In Part 3, we highlight some of the legal issues surrounding the use of AI/ML in collaborative drug discovery and some solutions for addressing these issues.
Topic: Life-sciences-and-healthcareSubscribe to Life-sciences-and-healthcare
AI and Drug Discovery, Part 2: In-Depth Look at the Mellody Project
Part 2 looks at an historic cross-competitor collaboration in the EU that is also leveraging blockchain technology to share large amounts of data to improve predictive models in drug discovery.
AI and Drug Discovery, Part 1: Collaborations Between Pharma and AI
In Part 1 of this update for 2019, we outline some of the key areas of advancements and discuss some of the recent partnerships between pharma companies and AI companies.
European Commission’s High-Level Expert Group on Artificial Intelligence Publishes Artificial Intelligence Ethics Guidelines
The Guidelines are the first deliverable under the European Union (EU’s) April 2018 Communication on Artificial Intelligence for Europe.
European Patent Office provides guidance on artificial intelligence patentability
The European Patent Office (EPO) recently issued guidance on the patenting of artificial intelligence (AI) and machine learning (ML) technologies. What does this mean for businesses in the field?
The Database Directive, AI and the data economy
Does the Database Directive protect machine-generated data and AI? That is one of the questions the European Commission considered in its recently published second evaluation of the Database Directive.
Artificial Intelligence and the future of work
AI’s impact on the workplace is contingent on many variables - the level of employees’ education and training, the cost of the technology, its adoption rate, regulation, ethics and how far AI creates new jobs.
British Prime Minister announces first AI and Data Grand Challenge
Theresa May has announced the first AI and Data grand challenge mission: to use data, AI and innovation to transform the prevention, early diagnosis and treatment of chronic diseases by 2030.
AI and Drug Development: The current landscape and IP considerations
AI has the potential to revolutionise the pharmaceuticals industry. Key considerations include how to monetise these innovations and what types of IP protection are available for AI-influenced drug discoveries?